id,provider,model,object,created,choices,usage
gen-1728196918-WyPdQ0xg7AUl6Mjk2ulI,Together,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196918,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Details**\n\n* **Title**: Improving physical and mental health in women with breast cancer undergoing anthracycline-based chemotherapy through wearable device-based aerobic exercise: a randomized controlled trial\n* **Journal**: Frontiers in Public Health\n* **Year**: 2024\n* **Volume**: 12\n* **Pages**: 1451101\n* **DOI**: 10.3389/fpubh.2024.1451101\n* **Clinical Trial Registration**: ChiCTR2300073667\n* **Registration URL**: https://www.chictr.org.cn/showproj.html?proj=200247\n\n**Authors**\n\n* **Li H**: College of Physical Education, South-Central Minzu University, Wuhan, Hubei, China; Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Sang D**: Department of Breast Medicine, Sanhuan Cancer Hospital, Beijing, China\n* **Gong L**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Wang B**: Discipline of Exercise and Sports Science, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia\n* **Wang Y**: Department of Ultrasound, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China\n* **Jia X**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Yu J**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Kong Z**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Liu H**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n* **Zhang Y**: Key Laboratory of Sports and Physical Fitness Health of Ministry of Education, Beijing Sport University, Beijing, China\n\n**Methods**\n\n* **Participants**: 40 adult women with breast cancer undergoing anthracycline-based chemotherapy\n* **Intervention**: Wearable device-based aerobic exercise (n=21) or no exercise intervention (n=19)\n* **Exercise protocol**: Moderate to high-intensity (50-90% HRmax) aerobic exercise during chemotherapy\n* **Assessments**: Health-related physical fitness level, physical activity energy expenditure, anxiety and depression scores, sleep quality, cancer-related fatigue, and overall quality of life (QoL)\n\n**Results**\n\n* **Primary outcomes**:\n\t+ Relative VO2peak (p=0.003)\n\t+ Handgrip strength (p<0.001)\n\t+ Physical activity energy expenditure (p<0.001)\n\t+ Anxiety scores (p=0.007)\n\t+ Depression scores (p=0.028)\n\t+ Sleep quality (p=0.010, p=0.004, p=0.007)\n\t+ Cancer-related fatigue (p<0.001, p<0.001)\n\t+ QoL (p<0.001, p=0.019)\n* **Secondary outcomes**:\n\t+ Gastrointestinal reactions (p=0.028)\n\t+ Myelosuppressive symptoms (p<0.001)\n\t+ Exercise-related adverse events\n\t+ Exercise adherence (mean 81.8%)\n\n**Conclusion**\n\n* Wearable device-based aerobic exercise during chemotherapy can be an effective adjunctive therapy to improve physical and mental health in breast cancer patients.', 'refusal': ''}}]","{'prompt_tokens': 967, 'completion_tokens': 749, 'total_tokens': 1716}"
gen-1728196967-yBsCSkIUrleZ7nayqJdF,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196967,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Details**\n\n* **Title**: Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial\n* **Journal**: Asian Pacific Journal of Cancer Prevention\n* **Year**: 2024\n* **Volume**: 25\n* **Issue**: 9\n* **Pages**: 3039-3049\n* **DOI**: 10.31557/APJCP.2024.25.9.3039\n* **PMID**: 39342581\n\n**Trial Design**\n\n* **Type**: Randomised Clinical Trial\n* **Phase**: III\n* **Intervention**: Palbociclib vs Ribociclib in combination with Fulvestrant\n* **Control Group**: No control group mentioned\n* **Randomization**: Concurrent randomised\n* **Blinding**: Open label\n\n**Inclusion/Exclusion Criteria**\n\n* **Inclusion**: Patients with pathologically proved ER+ HER2- metastatic breast cancer who either progressed on adjuvant hormonal or progressed on 1st line hormonal for metastatic disease\n* **Exclusion**: Not specified\n\n**Interventions**\n\n* **Arm A**: Palbociclib 125 mg/day orally for 3 weeks and 1 week rest, plus Fulvestrant\n* **Arm B**: Ribociclib 600 mg orally once daily for 3 weeks and 1 week rest, plus Fulvestrant\n* **Pre- and peri-menopausal women**: Received LHRH agonist Goserelin\n\n**Outcome Measures**\n\n* **Primary Outcomes**:\n\t+ Clinical Benefit Rate (CBR)\n\t+ Progression-Free Survival (PFS)\n\t+ Quality of Life (QOL)\n\t+ Toxicity profile\n* **Secondary Outcomes**:\n\t+ Median PFS\n\t+ Survival analysis\n\t+ QOL domains\n\n**Results**\n\n* **CBR**: No statistically significant difference between arms at 6 and 12 months\n* **PFS**: Median PFS 13 months for the whole population\n* **COX multivariate analysis**:\n\t+ Postmenopausal patients had 2.85 more likely to survive than premenopausal patients\n\t+ Patients with ECOG performance status 2 and 3 are 0.13 and 0.39 less likely to survive compared to patients with PS 1\n\t+ Dose reduction increased the likelihood of survival 3.36 compared with no dose reduction\n* **Median PFS**: 13.67 months in the Palbociclib arm and 12.69 months in the Ribociclib arm (no statistically significant difference)\n* **QOL**: Statistically significant improvement in insomnia in both arms and constipation in the Palbociclib arm alone\n* **Toxicity**: No statistically significant difference between the 2 arms\n\n**Conclusions**\n\n* Both Ribociclib and Palbociclib have similar CBR, PFS, and toxicity profile.', 'refusal': ''}}]","{'prompt_tokens': 900, 'completion_tokens': 644, 'total_tokens': 1544}"
gen-1728196995-fzbuWyquAdA4pL5B6WKj,Lepton,meta-llama/llama-3.1-70b-instruct,chat.completion,1728196995,"[{'logprobs': None, 'index': 0, 'message': {'role': 'assistant', 'content': ""Here is the structured data for the trial:\n\n**Trial Information**\n\n* Title: Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)\n* Journal: BMC Medical Informatics and Decision Making\n* Publication Date: 2024-09-27\n* DOI: 10.1186/s12911-024-02691-0\n* PubMed ID: 39334347\n* PMCID: PMC11430334\n\n**Authors**\n\n* Michel AM\n* Yi H\n* Amenta J\n* Collins N\n* Vaynrub A\n* Umakanth S\n* Anderson G\n* Arnold K\n* Law C\n* Pruthi S\n* Sandoval-Leon A\n* Shirley R\n* Perdekamp MG\n* Colonna S\n* Krisher S\n* King T\n* Yee LD\n* Ballinger TJ\n* Braun-Inglis C\n* Mangino DA\n* Wisinski K\n* DeYoung CA\n* Ross M\n* Floyd J\n* Kaster A\n* VanderWalde L\n* Saphner TJ\n* Zarwan C\n* Lo S\n* Graham C\n* Conlin A\n* Yost K\n* Agnese D\n* Jernigan C\n* Hershman DL\n* Neuhouser ML\n* Arun B\n* Crew KD\n* Kukafka R\n\n**Institutional Affiliations**\n\n* Columbia University Irving Medical Center (14 authors)\n* SWOG Statistics and Data Management Center (2 authors)\n* Mayo Clinic (1 author)\n* Miami Cancer Institute at Baptist Health South Florida (1 author)\n* Good Samaritan Hospital Corvallis (1 author)\n* Carle Cancer Center (1 author)\n* Huntsman Cancer Institute / University of Utah Medical Center (1 author)\n* Holy Redeemer Hospital and Medical Center (1 author)\n* Dana-Farber Brigham Cancer Center (1 author)\n* City of Hope Comprehensive Cancer Center (1 author)\n* Indiana University Simon Comprehensive Cancer Center (1 author)\n* University of Hawaii Cancer Center (1 author)\n* Memorial Sloan Kettering Cancer Center (1 author)\n* University of Wisconsin Carbone Cancer Center (1 author)\n* Kaiser Permanente NCORP (1 author)\n* Virginia Commonwealth University (1 author)\n* Cancer Care Specialists of Illinois, Heartland NCORP (1 author)\n* Sanford Roger Maris Cancer Center (1 author)\n* Baptist Memorial Health Care (1 author)\n* Aurora NCORP (1 author)\n* Lahey Hospital & Medical Center (1 author)\n* Loyola University Stritch School of Medicine (1 author)\n* Emory University Hospital/Winship Cancer Institute (1 author)\n* Providence Cancer Institute (1 author)\n* Cancer Research Consortium of West Michigan NCORP (1 author)\n* The Ohio State University Comprehensive Cancer Center (1 author)\n* SWOG Cancer Research Network (1 author)\n* Fred Hutchinson Cancer Center (1 author)\n* The University of Texas MD Anderson Cancer Center (1 author)\n\n**Trial Registration**\n\n* Registration Number: NCT04496739\n* Registration Date: Not specified\n* Registration Agency: National Institutes of Health ClinicalTrials.gov\n\n**Conflicts of Interest**\n\n* The authors declare no competing interests.\n\n**Funding Sources**\n\n* Not specified\n\n**Keywords**\n\n* Chemoprevention\n* Breast cancer\n* Decision support\n* Atypical hyperplasia\n* Lobular carcinoma in situ\n* Web-based intervention\n* Informed choice\n\n**Objectives**\n\n* To understand the attitudes and beliefs of providers about chemoprevention for breast cancer\n* To identify barriers and facilitators to chemoprevention among providers\n* To explore the use of decision support tools in promoting informed choice about chemoprevention\n\n**Intervention**\n\n* A qualitative analysis of pre-implementation interviews with providers about the use of decision support tools in promoting informed choice about chemoprevention.\n\n**Methods**\n\n* The study used a qualitative analysis of pre-implementation interviews with providers about the use of decision support tools in promoting informed choice about chemoprevention.\n\n**Outcomes**\n\n* Provider attitudes and beliefs about chemoprevention for breast cancer\n* Barriers and facilitators to chemoprevention among providers\n* The use of decision support tools in promoting informed choice about chemoprevention\n\n**Result**\n\n* Providers had varying attitudes and beliefs about chemoprevention for breast cancer\n* Providers reported barriers and facilitators to chemoprevention\n* Providers reported a lack of time and resources, difficulty communicating risk to patients, and concerns about patients' fear of side effects and anxiety as major barriers to chemoprevention\n* Providers expressed an interest in using decision support tools to promote informed choice about chemoprevention."", 'refusal': ''}}]","{'prompt_tokens': 1398, 'completion_tokens': 1003, 'total_tokens': 2401}"
gen-1728197016-pcfckhm0FrZjsqYm0dcT,Novita,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197016,"[{'logprobs': {'content': [], 'refusal': []}, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Research on the comprehensive child life intervention program (CCLIP) for adjusting medical fear in children with central nervous system (CNS) cancers: a randomized controlled trial study protocol\n* **DOI**: 10.1186/s40359-024-02028-6\n* **PMID**: 39334285\n* **PMCID**: PMC11438171\n* **Trial Registry**: Chinese Clinical Trial Registry\n* **Trial Registration Number**: ChiCTR2400082622\n* **Registration Date**: 2 April 2024\n\n**Authors**\n\n* **First Author**: Shen Y\n* **Co-Authors**:\n\t+ Wang M\n\t+ Wu XH\n\t+ Du J\n\t+ Wang YL\n\t+ Shi ZH\n\t+ Wang AN\n\t+ Zhang CH\n\t+ Ke Y\n\n**Affiliations**\n\n* **Shen Y, Shi ZH, Wang AN**: Department of Breast and Urological Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wang M**: Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Wu XH**: Nursing Department, Children's Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China\n* **Du J, Wang YL**: Department of Head and Neck and Pediatric Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Zhang CH**: Nursing Department, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n* **Ke Y**: Department of Head and Neck and Pediatric Oncology, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China\n\n**Study Design**\n\n* **Study Type**: Randomized Controlled Trial\n* **Number of Participants**: 38\n* **Inclusion Criteria**: Children with CNS cancers undergoing radiotherapy\n* **Exclusion Criteria**: Not specified\n* **Intervention**: Comprehensive Child Life Intervention Program (CCLIP) consisting of four key components: psychological adjustment and preparation, therapeutic play, pain management and coping strategies, and family support\n* **Control**: Standardized care\n* **Randomization**: Random number table method\n\n**Outcome Measures**\n\n* **Primary Outcome**: Effectiveness of CCLIP in reducing medical fear among children receiving radiation treatment for CNS cancers\n* **Secondary Outcomes**:\n\t+ Anxiety\n\t+ Depression\n\t+ Radiation adherence\n\t+ Quality of life among children\n\t+ Parental satisfaction\n\n**Data Collection**\n\n* **Data Collection Methods**: Questionnaires and on-site assessments\n* **Data Collection Time Points**: Four distinct time points:\n\t+ Day of admission (T0)\n\t+ First radiotherapy positioning (T1)\n\t+ Mid-radiotherapy (T2)\n\t+ Post-radiotherapy (T3)\n\n**Conflict of Interest**\n\n* **Statement**: The authors declare no competing interests."", 'refusal': ''}}]","{'prompt_tokens': 0, 'completion_tokens': 0, 'total_tokens': 0}"
gen-1728197040-Z8zuVYg3Tx907AKgiTPl,Novita,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197040,"[{'logprobs': {'content': [], 'refusal': []}, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""Here is the structured data from the trial:\n\n**Trial Details**\n\n* **Title**: Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer\n* **Journal**: Cancer Medicine\n* **Year**: 2024\n* **Volume**: 13\n* **Issue**: 18\n* **Pages**: e70236\n* **DOI**: 10.1002/cam4.70236\n* **PMCID**: PMC11426160\n* **PMID**: 39325020\n\n**Trial Design**\n\n* **Study Type**: Post hoc subgroup analysis of a phase 3 trial\n* **Number of Patients**: 56 (9.2% of the overall population)\n* **Randomization**: 1:1 to cemiplimab or chemotherapy\n* **Duration of Follow-up**: Median (range) 13.6 (6.0-25.3) months\n* **Treatment Arms**:\n\t+ Cemiplimab: 350 mg intravenously every 3 weeks\n\t+ Chemotherapy: Investigator's choice single-agent chemotherapy for up to 96 weeks\n\n**Endpoints**\n\n* **Primary Endpoint**: Overall survival (OS)\n* **Secondary Endpoints**:\n\t+ Progression-free survival (PFS)\n\t+ Objective response rate (ORR)\n\n**Results**\n\n* **OS**:\n\t+ Cemiplimab: 8.4 (7.0-not evaluable) months\n\t+ Chemotherapy: 9.4 (5.4-14.9) months\n\t+ Hazard ratio (HR): 0.86 (95% CI: 0.43-1.68)\n* **PFS**:\n\t+ Cemiplimab: 4.0 (1.4-8.2) months\n\t+ Chemotherapy: 3.7 (1.8-4.2) months\n\t+ HR: 0.90 (95% CI: 0.50-1.61)\n* **ORR**:\n\t+ Cemiplimab: 17.2%\n\t+ Chemotherapy: 7.4%\n\t+ Odds ratio: 2.47 (95% CI: 0.44-13.99)\n\n**Adverse Events**\n\n* **Incidence of Treatment-Emergent Adverse Events (TEAEs)**:\n\t+ Cemiplimab: 79.3% (any grade), 37.9% (grade ≥3)\n\t+ Chemotherapy: 100% (any grade), 66.7% (grade ≥3)\n\n**Authors**\n\n* **Lead Author**: Kosei Hasegawa\n* **Other Authors**: Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Ana Oaknin"", 'refusal': ''}}]","{'prompt_tokens': 0, 'completion_tokens': 0, 'total_tokens': 0}"
gen-1728197066-T1FENWPEevJpajle0kLD,Hyperbolic,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197066,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': '**Trial Data**\n\n* **Title:** On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.\n* **DOI:** 10.1186/s13058-024-01883-w\n* **PMCID:** PMC11423510\n* **PMID:** 39317942\n* **Journal:** Breast Cancer Research\n* **Year:** 2024\n* **Volume:** 26\n* **Issue:** 1\n* **Pages:** 138\n* **Authors:**\n\t+ Sinn, BV\n\t+ Sychra, K\n\t+ Untch, M\n\t+ Karn, T\n\t+ van Mackelenbergh, M\n\t+ Huober, J\n\t+ Schmitt, W\n\t+ Marmé, F\n\t+ Schem, C\n\t+ Solbach, C\n\t+ Stickeler, E\n\t+ Tesch, H\n\t+ Fasching, PA\n\t+ Schneeweiss, A\n\t+ Müller, V\n\t+ Holtschmidt, J\n\t+ Nekljudova, V\n\t+ Loibl, S\n\t+ Denkert, C\n\n**Trial Characteristics**\n\n* **Trial Type:** Randomized, prospective\n* **Number of Patients:** 297\n* **Condition:** Invasive breast cancer\n* **Intervention:** Neoadjuvant chemotherapy\n* **Outcome Measures:** Pathologic complete response (pCR), disease-free survival (DFS)\n\n**Results**\n\n* **pCR Rate:**\n\t+ Overall: 46%\n\t+ Hormone receptor-positive (HR+)/human epidermal growth factor 2-negative (HER2-): 3%\n\t+ Triple-negative (TNBC): 19%\n\t+ HER2+: 11%\n* **Residual Cancer:**\n\t+ Invasive tumor cells found in 70% of on-treatment biopsies\n\t+ Varying rates across subtypes (HR+/HER2-: 84%, TNBC: 62%, HER2+: 51%; p < 0.001)\n* **Predictive Values:**\n\t+ Sensitivity for predicting residual disease: 0.81\n\t+ Positive predictive value: 0.92\n\t+ Negative predictive value: 0.50\n* **Biomarkers:**\n\t+ Increasing tumor-infiltrating lymphocytes (TILs) from baseline to on-treatment biopsy associated with higher pCR likelihood (OR 1.034, 95% CI 1.013-1.056 per % increase; p = 0.001)\n\t+ Persisting or increased Ki-67 associated with lower pCR probability (OR 0.957, 95% CI 0.928-0.986; p = 0.004)\n\n**Conflict of Interest**\n\n* Multiple authors reported conflicts of interest, including employment, consultancy, honoraria, research funding, and patent holdings.', 'refusal': ''}}]","{'prompt_tokens': 2984, 'completion_tokens': 624, 'total_tokens': 3608}"
gen-1728197091-aNXy6ttoig67xzI7Wzjo,Hyperbolic,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197091,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': ""Here's the structured data for the trial:\n\n* **Title:** Voice-Activated Cognitive Behavioral Therapy for Insomnia: A Randomized Clinical Trial.\n* **Publication Date:** September 3, 2024\n* **Journal:** JAMA Network Open\n* **DOI:** 10.1001/jamanetworkopen.2024.35011\n* **PMID:** 39316400\n* **PMCID:** PMC11423177\n* **ClinicalTrials.gov Identifier:** NCT05233800\n\n**Authors:**\n\n1. Starling CM\n\t* Affiliation: Implementation Science, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC\n2. Greenberg D\n\t* Affiliation: Media Rez, Washington, DC\n3. Lewin D\n\t* Affiliation: Sleep Health and Wellness Center, Santa Barbara, California\n\t* Conflict of Interest: Received grants from the Sleep Health and Wellness Center during the conduct of the study\n4. Shaw C\n\t* Affiliation: Media Rez, Washington, DC\n5. Zhou ES\n\t* Affiliation: Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts\n6. Lieberman D\n\t* Affiliation: George Washington University, Washington, DC\n7. Chou J\n\t* Affiliation: Center for Biostatistics, Informatics, and Data Science, MedStar Health Research Institute, Hyattsville, Maryland\n8. Arem H\n\t* Affiliation: Implementation Science, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC; Department of Oncology, Georgetown University, Washington DC\n\t* Conflict of Interest: Received grants from the National Cancer Institute (NCI) during the conduct of the study and funding from the Maryland Department of Health and the Centers for Disease Control and Prevention outside the submitted work\n\n**Trial Information:**\n\n* **Objective:** To determine the efficacy of a CBT-I-informed, voice-activated, internet-delivered program for improving insomnia symptoms among breast cancer survivors.\n* **Design:** Randomized Clinical Trial\n* **Setting:** In-home\n* **Participants:** Breast cancer survivors with insomnia (Insomnia Severity Index [ISI] score >7)\n* **Inclusion Criteria:**\n\t+ Female\n\t+ Aged 18 years or older\n\t+ Completed curative treatment more than 3 months before enrollment\n\t+ Had not undergone other behavioral sleep treatments in the prior year\n* **Intervention:** Voice-interactive CBT-I program delivered through a smart speaker for 6 weeks\n* **Control:** Educational control\n* **Randomization:** 1:1\n* **Sample Size:** 76 (38 in each group)\n* **Completion Rate:** 92.1% (70/76)\n\n**Results:**\n\n* **Primary Outcome:** Change in ISI scores\n\t+ Intervention group: -8.4 (4.7) points\n\t+ Control group: -2.6 (3.5) points\n\t+ P-value: < 0.001\n\t+ Cohen d: 1.41 (95% CI: 0.87-1.94)\n* **Secondary Outcomes:**\n\t+ Sleep quality: statistically significant improvement in the intervention group\n\t+ Wake after sleep onset: statistically significant improvement in the intervention group (9.54 minutes; 95% CI: 1.93-17.10 minutes)\n\t+ Sleep onset latency: statistically significant improvement in the intervention group (8.32 minutes; 95% CI: 1.91-14.70 minutes)\n\t+ Total sleep time: no statistically significant difference\n\t+ Sleep efficiency: statistically significant improvement in the intervention group (-0.04%; 95% CI: -0.07% to -0.01%)"", 'refusal': ''}}]","{'prompt_tokens': 1104, 'completion_tokens': 798, 'total_tokens': 1902}"
gen-1728197123-Oe0Yi31MarqCsDt1byS9,Lepton,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197123,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Acellular Dermal Matrix without Basement Membrane in Immediate Prepectoral Breast Reconstruction: A Randomized Controlled Trial\n* **Journal**: Plastic and Reconstructive Surgery\n* **Year**: 2024\n* **Volume**: 154\n* **Issue**: 4\n* **Pages**: 649e-655e\n* **DOI**: 10.1097/PRS.0000000000011117\n* **PMID**: 39314097\n\n**Authors**\n\n* **Han WY**: Department of Plastic and Reconstructive Surgery, Yongin Severance Hospital, Yonsei University College of Medicine\n* **Kim DJ**: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine\n* **Lee YS**: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine\n* **Eom JS**: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine\n* **Kim EK**: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine\n* **Han HH**: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine\n\n**Trial Design**\n\n* **Type**: Randomized Controlled Trial\n* **Blinding**: Single-blind\n* **Intervention**: Acellular dermal matrix (ADM) with or without basement membrane\n* **Control**: ADM with basement membrane\n\n**Participants**\n\n* **Total**: 56 patients\n* **Group 1**: ADM with basement membrane (n = 30, 53.6%)\n* **Group 2**: ADM without basement membrane (n = 26, 46.4%)\n\n**Outcomes**\n\n* **Primary outcome**: Clinical outcomes, including complications and breast shape change\n* **Secondary outcome**: Seroma rate\n* **Results**:\n\t+ No statistically significant differences in overall rate of complications or breast shape change between the two groups\n\t+ Higher rate of seromas in the ADM with basement membrane group (10% vs 0%, P = 0.09)\n\n**Conclusion**\n\n* **Summary**: ADM without basement membrane in implant-based breast reconstruction is safe and has mechanical properties of lower tensile strength and higher elasticity.\n* **Clinical question/level of evidence**: Therapeutic, II.', 'refusal': ''}}]","{'prompt_tokens': 615, 'completion_tokens': 518, 'total_tokens': 1133}"
gen-1728197146-8Gbq1s2oyVX0cYvJVFcV,Hyperbolic,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197146,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system\n* **DOI**: 10.1007/s00520-024-08855-y\n* **PubMed ID**: 39304604\n* **Trial Registration**: NCT03021174 (registered on ClinicalTrials.gov in January 2017)\n\n**Study Design**\n\n* **Study Type**: Randomized controlled pilot study\n* **Interventions**:\n\t+ Exercise group: 12 weeks of home-based, individually tailored, moderate intensity, progressive walking, and resistance training\n\t+ Active control group: 12 weeks of nutrition education\n* **Primary Clinical Outcome**: CIPN-20 (chemotherapy-induced peripheral neurotoxicity symptoms)\n\n**Participants**\n\n* **Number of Participants**: 19\n* **Age**: 65 ± 11 years old\n* **Sex**: 52% women\n* **Cancer Types**: Breast, gastrointestinal, multiple myeloma\n\n**Outcome Measures**\n\n* **CIPN Symptoms**: CIPN-20 (primary clinical outcome)\n* **CIPN Signs**: Tactile sensitivity using monofilaments\n* **Physical Function**: Leg strength\n* **Functional Connectivity**: Task-free (""resting"") fMRI to assess functional connectivity in the interoceptive brain system, involving the salience and default mode networks\n\n**Results**\n\n* **Feasibility**: 74-89% complete data across measures\n* **Acceptability**: 95% retention\n* **Exercise Effects**:\n\t+ CIPN symptoms: moderate/large beneficial effects (ES = -0.9 at mid-intervention; ES = -0.5 at post-intervention)\n\t+ CIPN signs: moderate/large beneficial effects (ES = -1.0 and -0.1)\n\t+ Physical function: small beneficial effects (ES = 0.4 and 0.3)\n* **Changes in Interoceptive Brain Circuitry**:\n\t+ Patients with worse CIPN after neurotoxic chemotherapy had lower functional connectivity within the default mode network and higher functional connectivity within the salience network\n\t+ Exercise tended to increase hypoconnectivity and decrease hyperconnectivity seen in CIPN\n\n**Conclusion**\n\n* Exercise during neurotoxic chemotherapy is feasible and may attenuate CIPN symptoms and signs, perhaps via changes in interoceptive brain circuitry.\n* Future work should test for replication with larger samples.', 'refusal': ''}}]","{'prompt_tokens': 965, 'completion_tokens': 534, 'total_tokens': 1499}"
gen-1728197166-hCxsCVtbyTiSCiklcfsU,DeepInfra,meta-llama/llama-3.1-70b-instruct,chat.completion,1728197166,"[{'logprobs': None, 'finish_reason': 'stop', 'index': 0, 'message': {'role': 'assistant', 'content': 'Here is the structured data for the trial:\n\n**Trial Information**\n\n* **Title**: A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.\n* **Journal**: BMC Cancer\n* **Year**: 2024\n* **Volume**: 24\n* **Issue**: 1\n* **Pages**: 1143\n* **DOI**: 10.1186/s12885-024-12892-5\n* **PMID**: 39272058\n* **PMC**: PMC11395217\n\n**Trial Design**\n\n* **Type**: Randomized, multicenter, open-label, active-controlled non-inferiority study\n* **Phase**: III\n* **Number of centers**: 13\n* **Number of patients**: 239\n\n**Interventions**\n\n* **Intervention 1**: Efbemalenograstim alfa (F-627) - single 20 mg subcutaneous injection on day 3 of each cycle\n* **Intervention 2**: Filgrastim (GRAN) - daily subcutaneous injection of 5 µg/kg/d starting from day 3 of each cycle\n\n**Outcome Measures**\n\n* **Primary endpoint**: Duration of grade 3 or 4 neutropenia in cycle 1\n* **Secondary endpoints**: Duration of grade 3 or 4 neutropenia in cycles 2-4, incidence of grade 3 or 4 neutropenia, ANC nadir\n\n**Results**\n\n* **Primary endpoint**: Mean (SD) duration of grade 3 or 4 neutropenia in cycle 1 was 0.68 (1.10) days for F-627 and 0.71 (0.95) days for filgrastim\n* **Hodges-Lehmann estimate**: Between-group median difference (F-627 vs filgrastim) in the duration of grade 3 or 4 neutropenia in cycle 1 was 0 day\n* **Upper limit of one-sided 97.5% CI**: 0 day, within the prespecified non-inferiority margin of 1-day\n\n**Safety**\n\n* **Single fixed dose of F-627**: Well tolerated and as safe as standard daily filgrastim\n\n**Registration**\n\n* **ClinicalTrials.gov**: NCT04174599, registered on 22/11/2019', 'refusal': ''}}]","{'prompt_tokens': 1354, 'completion_tokens': 530, 'total_tokens': 1884}"
